Compare · BDSX vs HUM
BDSX vs HUM
Side-by-side comparison of Biodesix Inc. (BDSX) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDSX and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $48.84B, about 223.2x BDSX ($218.8M).
- Over the past year, BDSX is up 247.2% and HUM is up 83.2% - BDSX leads by 164.0 points.
- HUM has been more active in the news (6 items in the past 4 weeks vs 2 for BDSX).
- HUM has more recent analyst coverage (25 ratings vs 9 for BDSX).
- Company
- Biodesix Inc.
- Humana Inc.
- Price
- $21.25-2.52%
- $406.54+0.17%
- Market cap
- $218.8M
- $48.84B
- 1M return
- +42.62%
- +10.23%
- 1Y return
- +247.22%
- +83.24%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 2
- 6
- Recent ratings
- 9
- 25
Biodesix Inc.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest BDSX
- Chairman Patience John converted options into 1,361 shares, increasing direct ownership by 6% to 25,383 units (SEC Form 4)
- Roth Capital initiated coverage on Biodesix with a new price target
- H.C. Wainwright initiated coverage on Biodesix with a new price target
- SEC Form EFFECT filed by Biodesix Inc.
- SEC Form S-3 filed by Biodesix Inc.
- Biodesix to Participate in Upcoming Investor Conferences
- SEC Form 8-K filed by Biodesix Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biodesix Inc.
- Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
- SEC Form 10-Q filed by Biodesix Inc.
Latest HUM
- Humana upgraded by Wells Fargo with a new price target
- SEC Form 4 filed by Director Hilzinger Kurt J
- The Humana Foundation Deepens Investment in Emotional Health, Announcing Over $12 Million in New Grants
- SEC Form 11-K filed by Humana Inc.
- SEC Form 11-K filed by Humana Inc.
- Humana Inc. to Release Second Quarter 2026 Results on July 29, 2026
- Humana Awarded Statewide Illinois HealthChoice Medicaid Contract, Expanding Access to Care Across the State
- Humana Announces Agreement to Divest Minority Interest in Gentiva
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach